We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




LabChip Technology Licensed to Agilent

By Biotechdaily staff writers
Posted on 02 Aug 2005
A nonexclusive license to use the LabChip technology of Caliper Life Sciences, Inc. More...
(Hopkinton, MA, USA), has been granted by Caliper to Agilent Technologies, Inc. (Palo Alto, CA, USA), for the development of clinical diagnostic applications.

The license enables Agilent to use a majority of Caliper's microfluidics patent estate in developing applications for Agilent's 2100 Bioanalyzer, its 5100 automated Lab-on-a-Chip platform, and future instrument platforms. Under a separate supply agreement, Agilent agreed to use Caliper as its exclusive supplier of planar LabChip products for its 2100 Bioanalzyer and future platforms for the next five years.

Under the terms of the agreement, Agilent will pay an upfront licensing fee to Caliper plus royalties on future sales of diagnostic LabChip products covered under the agreement. Further details were not disclosed.

"Adding the Agilent diagnostic license to our LabChip-Driven program is an important milestone for our business,” noted Kevin Hrusovsky, president and CEO of Caliper. "We believe our LabChip technology will play a leading role in the evolution of the diagnostics market as personalized medicine becomes mainstream. Where testing must be increasingly integrated, there is a real market need for cost-effective solutions that are able to migrate closer to the patient while still producing extremely high-quality results.”





Related Links:
Agilent
Caliper

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.